Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 827
interventional 636
Observational 181
Registry 10

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 430
Drug|placebo 108
Biological|Drug 26
Biological|Drug|placebo 17
Biological 15
Other 10
Behavioral 7
Device 5
Biological|Other 2
Diagnostic Test 2
Dietary Supplement 2
Dietary Supplement|Drug 2
Dietary Supplement|placebo 2
Biological|Drug|Procedure 1
Biological|placebo 1
Diagnostic Test|Drug 1
Drug|Other 1
Drug|Other|Procedure 1
Drug|Procedure 1
Other|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
NA 143
United States 123
United States|Puerto Rico 30
China 23
Japan 20
Taiwan 19
Egypt 16
France 16
Spain 12
Canada 10
Russian Federation 9
Brazil 8
Australia 6
Germany 6
India 6
New Zealand 6
United States|Canada 6
Israel 5
Korea, Republic of 5
Switzerland 5
Austria 4
Netherlands 4
United Kingdom 4
Iran, Islamic Republic of 3
Pakistan 3
Belgium 2
Belgium|France 2
China|Korea, Republic of 2
Cuba 2
Italy 2
Rwanda 2
Saudi Arabia 2
Sweden 2
United States|France|Puerto Rico 2
Algeria|Australia|Austria|Belgium|Bulgaria|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Mexico|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Argentina|Australia|Canada|Mexico|New Zealand|Thailand 1
Australia|Austria|United States|Canada|France|Germany|Italy|Puerto Rico|Spain 1
Australia|Belgium|Canada|Germany|Norway|Switzerland|United Kingdom 1
Australia|Brazil|France|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Australia|Canada|Czech Republic|France|Germany|Israel|Poland|Romania 1
Australia|Canada|France|Germany|Greece|India|Italy|Poland|Spain|Taiwan|Thailand|United Kingdom 1
Australia|France|Germany|Italy|Spain|United Kingdom 1
Australia|Germany|Poland|Romania|Spain|Taiwan 1
Australia|New Zealand 1
Austria|Belgium|France|Germany|Netherlands|Spain 1
Austria|Belgium|France|Germany|Saudi Arabia|Spain|United Kingdom 1
Austria|Belgium|France|Germany|Spain|United Kingdom 1
Austria|Brazil|France|Greece|Indonesia|Italy|Turkey|United Arab Emirates 1
Austria|France|Germany|United Kingdom 1
Austria|Germany|Hungary|Poland|Romania|Spain 1
Belarus|India|Russian Federation|Thailand 1
Belgium|Brazil|France|Austria|United States|Australia|Germany|Ireland|Mexico|Poland|Spain|Sweden|United Kingdom 1
Belgium|Canada|Germany|Poland|Singapore|Spain 1
Belgium|France|Germany|Hungary|Spain|United Kingdom 1
Belgium|France|Germany|Italy|Poland|Romania|Spain 1
Belgium|Germany 1
Belgium|Germany|Hungary|Ireland|Luxembourg|Portugal|Russian Federation|United Kingdom 1
Belgium|Mauritius|Moldova, Republic of 1
Belgium|Moldova, Republic of 1
Bulgaria|Israel|Romania 1
Canada|United States|Austria|Brazil|France|Germany|Italy|Mexico|Puerto Rico|Spain|United Kingdom 1
China|Korea, Republic of|Russian Federation 1
China|Korea, Republic of|Singapore 1
China|Korea, Republic of|Taiwan 1
Colombia 1
Czech Republic 1
Czechia|Slovakia 1
Denmark 1
France|Belgium|Germany|Netherlands|Poland|United Kingdom 1
France|Georgia|Moldova, Republic of 1
France|Germany|Greece|Italy|Spain 1
France|Germany|Netherlands 1
France|Germany|Switzerland 1
France|Germany|United States|Canada|Italy|Puerto Rico|Spain 1
France|Moldova, Republic of|Romania 1
France|Netherlands|Poland 1
France|New Zealand|Poland 1
France|Sweden|United Kingdom 1
France|United States|Belgium|Brazil|Canada|Denmark|Germany|Hungary|Netherlands|Poland|Puerto Rico|Romania|Russian Federation|Sweden|United Kingdom 1
Germany|Poland|Romania 1
Germany|Poland|Spain 1
Germany|Poland|Sweden|United Kingdom 1
Germany|Serbia|United States|Argentina|Belgium|Chile|Egypt|Estonia|France|Greece|Italy|Kuwait|Latvia|Lebanon|Lithuania|Macedonia, The Former Yugoslav Republic of|Mexico|Oman|Pakistan|Peru|Portugal|Qatar|Romania|Slovakia|Sweden|Switzerland|Syrian Arab Republic|Taiwan|Turkey|United Arab Emirates|Venezuela 1
Germany|United States 1
Germany|United States|Australia|Austria|Canada|France|Italy|Puerto Rico|Spain|United Kingdom 1
Israel|United States|Argentina|Australia|Belgium|Brazil|Canada|France|Germany|India|Korea, Republic of|Malaysia|Mexico|Poland|Puerto Rico|Singapore|Spain|Sweden|Taiwan|Thailand|United Kingdom 1
Italy|Portugal|United States|Belgium|Brazil|Canada|France|Germany|Greece|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Korea, Republic of|Russian Federation|Taiwan 1
Korea, Republic of|Taiwan|Thailand 1
Mauritius|Moldova, Republic of|New Zealand|United Kingdom 1
Mauritius|United Kingdom 1
Mexico 1
Moldova, Republic of 1
Norway 1
Poland 1
Puerto Rico 1
Russian Federation|Sweden 1
Spain|Sweden|Puerto Rico|Poland|United States|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Israel|Netherlands|Switzerland|United Kingdom 1
United Kingdom|Australia|Canada|Israel|New Zealand|Spain 1
United States|Argentina 1
United States|Argentina|Australia|Austria|Brazil|Canada|Denmark|France|Germany|Israel|Italy|Poland|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Canada|Czech Republic|France|Germany|Korea, Republic of|Netherlands|Portugal|Romania|Spain|Switzerland|United Kingdom 1
United States|Argentina|Australia|Canada|France|Israel|Italy|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Argentina|Belgium|Canada|France|Germany|Italy|Mexico|Poland|Russian Federation|Spain|United Kingdom 1
United States|Argentina|Canada|Puerto Rico 1
United States|Argentina|France|Germany|Hungary|Spain 1
United States|Australia|Austria|Belgium|Brazil|Canada|Germany|Mexico|Puerto Rico|Switzerland 1
United States|Australia|Austria|Brazil|Canada|France|Germany|Italy|Mexico|Poland|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Austria|Canada|Czech Republic|Estonia|France|Germany|Italy|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|Canada|Czech Republic|France|Germany|India|Israel|Italy|Poland|Puerto Rico|Romania|Spain|United Kingdom 1
United States|Australia|Austria|Canada|France|Germany|Italy 1
United States|Australia|Austria|France|Germany|New Zealand|Portugal|Romania|Spain|Switzerland 1
United States|Australia|Belgium|Brazil|Canada|Czech Republic|France|Germany|Hong Kong|India|Israel|Italy|Korea, Republic of|Netherlands|Pakistan|Poland|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|France|Germany|Israel|Netherlands|Poland|Puerto Rico|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Greece|Italy|New Zealand|Portugal|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|New Zealand|Singapore|South Africa|Vietnam 1
United States|Australia|Belgium|Germany|Puerto Rico|Spain|Taiwan 1
United States|Australia|Brazil|France|Greece|Italy|Poland|Puerto Rico|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Czechia|Germany|Israel|Korea, Republic of|Malaysia|New Zealand|Puerto Rico|Romania|Russian Federation|Singapore|Taiwan 1
United States|Australia|Canada|France 1
United States|Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|Spain 1
United States|Australia|Canada|France|Germany|New Zealand|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|New Zealand|Switzerland|United Kingdom 1
United States|Australia|Canada|France|New Zealand|Poland|Slovakia 1
United States|Australia|Canada|France|Puerto Rico 1
United States|Australia|Canada|New Zealand|Puerto Rico 1
United States|Australia|Germany|New Zealand|Poland 1
United States|Australia|New Zealand 1
United States|Australia|Puerto Rico 1
United States|Austria|Belgium|Canada|Czech Republic|France|Germany|Italy|Poland|Spain|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Japan|Portugal|Puerto Rico|Spain|Switzerland|United Kingdom 1
United States|Austria|Belgium|France|Germany|Netherlands|Poland|United Kingdom 1
United States|Austria|Canada|France|Germany|Hungary|Ireland|Italy|Netherlands|Portugal|Romania|Russian Federation|Spain|United Kingdom 1
United States|Austria|Canada|France|Germany|Spain 1
United States|Belgium|Bulgaria|France|Germany|Puerto Rico 1
United States|Belgium|Canada|Germany|Japan|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Belgium|Germany|Puerto Rico|Spain 1
United States|Belgium|Netherlands|Puerto Rico 1
United States|Brazil|France|Germany|Italy|Spain|Switzerland|United Kingdom 1
United States|Brazil|France|New Zealand|Sweden 1
United States|Bulgaria|Canada|Czechia|France|Greece|Hungary|Ireland|Israel|Italy|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|United Kingdom|Vietnam 1
United States|Bulgaria|Puerto Rico|Romania 1
United States|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Canada|France|Germany|Portugal|Puerto Rico|Spain|United Kingdom 1
United States|Canada|Germany 1
United States|Canada|Germany|Greece|Italy|Korea, Republic of|Poland|Puerto Rico|Spain|Sweden 1
United States|Canada|Germany|Poland|United Kingdom 1
United States|Canada|New Zealand|Puerto Rico 1
United States|France 1
United States|France|Germany|Italy|Puerto Rico|Spain|United Kingdom 1
United States|France|Germany|New Zealand 1
United States|France|Germany|New Zealand|Spain 1
United States|France|Germany|Puerto Rico|United Kingdom 1
United States|France|Germany|Spain 1
United States|Germany|Netherlands|Poland|Puerto Rico|Slovakia 1
United States|Germany|Poland|Sweden 1
United States|Germany|Spain|United Kingdom 1
United States|India|Australia|Belgium|Brazil|Canada|Czech Republic|Egypt|France|Germany|Greece|Israel|Italy|Korea, Republic of|Pakistan|Poland|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Taiwan|Ukraine 1
United States|New Zealand 1
Vietnam 1

Sites per Study

Site_count Study_Count
1 323
2 35
3 15
4 15
5 16
6 17
7 8
8 12
9 5
10 7
11 11
12 3
13 3
14 3
15 8
16 8
17 4
18 7
19 8
20 4
21 5
22 4
23 4
24 5
25 7
26 5
27 1
28 4
29 1
30 1
31 1
32 6
33 1
34 2
35 2
37 2
38 4
39 2
40 1
41 2
42 1
43 4
44 1
45 1
46 1
48 4
49 1
51 2
52 2
53 2
55 2
56 2
59 1
60 1
63 2
66 3
67 4
68 1
71 1
82 1
87 1
88 1
91 1
93 2
97 1
100 2
101 2
102 1
104 1
109 1
113 1
114 1
116 1
121 1
132 1
144 1
159 1
165 1
175 1
184 1
187 1
191 1
210 1
227 1

Phase

Phase Study_Count
Phase 2 191
Phase 3 170
Phase 4 108
Phase 1 81
N/A 40
Phase 1/Phase 2 26
Phase 2/Phase 3 19
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 147
2 199
3 87
4 61
5 20
6 18
7 10
8 7
9 6
10 3
11 2
12 4
13 1
14 1
15 2
20 1
22 2
27 1
NA 64

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 52 13.000 5.00000 9.00000 5.0000 30.0000 10.0000 6.000
1st Qu. 52 30.000 26.00000 24.00000 40.0000 100.0000 104.0000 50.000
Median 52 71.500 37.00000 36.00000 75.0000 150.0000 204.5000 102.000
Mean 52 2315.026 47.33333 53.79167 131.5798 296.3158 372.4059 2402.454
3rd Qu. 52 146.250 64.00000 76.00000 168.2500 385.5000 466.7500 302.000
Max. 52 50000.000 135.00000 178.00000 765.0000 1224.0000 5000.0000 221855.000

Trial Group Type

group_type Group_Count
Experimental 1323
Active Comparator 226
Placebo Comparator 89
NA 64
Other 27
No Intervention 20
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 409
Single Group Assignment 195
Crossover Assignment 13
NA 10
Sequential Assignment 7
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 587
NA 13
Health Services Research 8
Basic Science 7
Prevention 7
Diagnostic 6
Other 4
Screening 2
Supportive Care 2

Observational Studies

Studies by Country

Country Study_Count
NA 54
United States 17
France 7
Spain 7
Netherlands 6
China 5
Italy 5
Korea, Republic of 5
Australia 4
Japan 4
Russian Federation 4
United States|Puerto Rico 4
Brazil 3
Canada 3
Germany 3
Israel 3
Mexico 3
Switzerland 3
Taiwan 3
Austria 2
Belgium 2
Denmark 2
India 2
Turkey 2
Australia|United States|Austria|Belgium|Canada|Czechia|Estonia|France|Germany|Italy|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1
Belgium|France|Germany|Netherlands|Switzerland|United Kingdom 1
Bulgaria 1
China|Japan 1
Colombia 1
Czech Republic 1
Egypt 1
France|Austria|Belgium|Greece|Israel|Italy|Poland|Portugal|Switzerland 1
France|Hungary|Austria|Brazil|Canada|Croatia|Macedonia, The Former Yugoslav Republic of|Mexico|Morocco|Poland|Romania|Serbia|Slovenia|Sweden 1
Georgia 1
Greece 1
Greece|Belgium|Egypt|Estonia|France|Germany|Hungary|Ireland|Italy|Kuwait|Lebanon|Macedonia, The Former Yugoslav Republic of|Morocco|Oman|Pakistan|Portugal|Qatar|Romania|Saudi Arabia|Serbia|Sweden|Switzerland|Syrian Arab Republic|Taiwan|Turkey|United Arab Emirates|United Kingdom 1
Hong Kong 1
Hungary 1
Italy|Belgium|Ireland|United Kingdom 1
Korea, Republic of|Russian Federation 1
Korea, Republic of|Taiwan 1
Lebanon|Albania|Algeria|Bahrain|Belgium|Bosnia and Herzegovina|Brazil|Egypt|Greece|Hungary|India|Iran, Islamic Republic of|Italy|Korea, Republic of|Kuwait|Macedonia, The Former Yugoslav Republic of|Morocco|Pakistan|Poland|Portugal|Qatar|Romania|Serbia|Slovakia|United Arab Emirates 1
Poland 1
Puerto Rico 1
Senegal 1
Singapore 1
Slovenia 1
Thailand 1
United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Canada|Finland|France|Germany|Greece|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Puerto Rico|Romania|Spain 1
United States|Argentina|Australia|Brazil|Canada|Denmark|France|Germany|Ireland|Italy|Japan|Korea, Republic of|Mexico|Poland|Puerto Rico|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|Czechia|Estonia|France|Germany|Italy|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1

Sites per Study

Site_count Study_Count
1 123
2 7
3 4
4 5
5 1
6 2
7 1
9 3
10 3
11 1
12 1
14 1
18 1
19 1
21 1
26 2
27 1
30 1
34 1
37 1
46 1
57 1
61 1
66 1
70 1
73 1
74 1
75 1
101 1
104 1
106 1
156 1
161 1
170 1
261 1
266 1
272 1
323 1
325 1
388 1

Enrollment Metrics

Measure Observational
Min 2.00
1st Qu 100.00
Median 274.50
Mean 1819.75
3rd Qu 752.00
Max 150000.00

Observation Model

observational_model Study_Count
Cohort 127
Case-Only 22
NA 11
Case Control 9
Case-Control 5
Other 4
Ecologic or Community 2
Defined Population, Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 139
Retrospective 18
Cross-Sectional 11
Other 9
NA 3
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
Spain 2
Austria 1
China 1
Egypt 1
Germany 1
Japan 1
United States 1
United States|Australia|Belgium|Germany|Italy|New Zealand|Russian Federation|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|Spain|United Kingdom 1

Sites per Study

Site_count Study_Count
1 7
18 1
48 1
138 1

Enrollment Metrics

Measure Registries
Min 100.00
1st Qu 306.25
Median 529.00
Mean 859.30
3rd Qu 1026.25
Max 2974.00

Registry Model

observational_model Study_Count
Cohort 8
Case-Only 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 9
Other 1

Follow-up

target_duration Study_Count
24 Weeks 2
3 Years 2
5 Years 2
1 Year 1
10 Years 1
144 Weeks 1
48 Weeks 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04208035 Hepatitis C Elimination in the Netherlands https://ClinicalTrials.gov/show/NCT04208035 Recruiting Radboud University 2021-01-01
NCT03366610 Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens https://ClinicalTrials.gov/show/NCT03366610 Completed Bristol-Myers Squibb 2019-04-30
NCT03343925 Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings https://ClinicalTrials.gov/show/NCT03343925 Recruiting Kirby Institute 2021-07-01
NCT03313154 Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related https://ClinicalTrials.gov/show/NCT03313154 Completed Azienda Ospedaliero Universitaria di Cagliari 2018-07-31
NCT03303599 Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 https://ClinicalTrials.gov/show/NCT03303599 Completed AbbVie 2020-01-24
NCT03248622 Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT03248622 Completed National Institutes of Health Clinical Center (CC) 2019-05-28
NCT03200379 Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan https://ClinicalTrials.gov/show/NCT03200379 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2037-06-15
NCT03181074 Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults https://ClinicalTrials.gov/show/NCT03181074 Completed Bristol-Myers Squibb 2019-08-19
NCT03149289 Hepatitis C Virus Infection in Patients With Hemoglobinopathies https://ClinicalTrials.gov/show/NCT03149289 Completed Società Italiana Talassemie ed Emoglobinopatie 2016-03-01
NCT03144440 Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel https://ClinicalTrials.gov/show/NCT03144440 Active, not recruiting Carmel Medical Center 2020-01-01
NCT03088917 ‘Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat’ https://ClinicalTrials.gov/show/NCT03088917 Completed Radboud University 2019-12-01
NCT03063723 Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs https://ClinicalTrials.gov/show/NCT03063723 Completed Third Affiliated Hospital, Sun Yat-Sen University 2016-12-01
NCT03053180 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation https://ClinicalTrials.gov/show/NCT03053180 Completed AbbVie 2017-12-18
NCT03038763 Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers https://ClinicalTrials.gov/show/NCT03038763 Completed University of Pennsylvania 2019-06-30
NCT03002818 Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) https://ClinicalTrials.gov/show/NCT03002818 Completed AbbVie 2018-04-25
NCT02945228 Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2 https://ClinicalTrials.gov/show/NCT02945228 Completed AbbVie 2019-07-26
NCT02851069 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia https://ClinicalTrials.gov/show/NCT02851069 Completed AbbVie 2018-08-30
NCT02850289 APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin https://ClinicalTrials.gov/show/NCT02850289 Completed Hoffmann-La Roche 2008-10-31
NCT02817594 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02817594 Completed AbbVie 2018-03-07
NCT02807402 Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania https://ClinicalTrials.gov/show/NCT02807402 Completed AbbVie 2017-08-04
NCT02803138 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02803138 Completed AbbVie 2018-10-21
NCT02798315 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study https://ClinicalTrials.gov/show/NCT02798315 Completed AbbVie 2017-06-12
NCT02788682 Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy https://ClinicalTrials.gov/show/NCT02788682 Completed Cairo University 2015-07-31
NCT02785835 Hepatocellular Carcinoma in HIV-infected Patients https://ClinicalTrials.gov/show/NCT02785835 Recruiting Hospital Universitario de Valme 2016-12-31
NCT02783976 Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice https://ClinicalTrials.gov/show/NCT02783976 Completed Gilead Sciences 2018-06-20
NCT02758509 Impact of Antiviral Therapy on Gastroesophageal Varices. https://ClinicalTrials.gov/show/NCT02758509 Completed Parc de Salut Mar 2017-06-15
NCT02726022 A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels https://ClinicalTrials.gov/show/NCT02726022 Completed Hoffmann-La Roche 2011-07-31
NCT02725866 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02725866 Completed AbbVie 2017-10-31
NCT02714712 SR-BI and Antiviral Treatment Response in HCV https://ClinicalTrials.gov/show/NCT02714712 Completed Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation 2016-07-31
NCT02669940 Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation https://ClinicalTrials.gov/show/NCT02669940 Completed AbbVie 2017-07-04
NCT02640547 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02640547 Completed AbbVie 2017-03-29
NCT02636608 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary https://ClinicalTrials.gov/show/NCT02636608 Completed AbbVie 2018-05-23
NCT02629172 Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 https://ClinicalTrials.gov/show/NCT02629172 Completed AbbVie 2019-02-28
NCT02618928 The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France https://ClinicalTrials.gov/show/NCT02618928 Completed AbbVie 2018-03-29
NCT02615145 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) https://ClinicalTrials.gov/show/NCT02615145 Completed AbbVie 2018-03-26
NCT02601820 The Patient-Reported Outcomes Project of HCV-TARGET https://ClinicalTrials.gov/show/NCT02601820 Completed University of North Carolina, Chapel Hill 2018-07-31
NCT02592057 Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India https://ClinicalTrials.gov/show/NCT02592057 Completed Gilead Sciences 2017-11-30
NCT02583243 Project BEST: Buprenorphine Entry Into Substance Abuse Treatment https://ClinicalTrials.gov/show/NCT02583243 Completed Yale University 2008-08-31
NCT02582671 The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland https://ClinicalTrials.gov/show/NCT02582671 Completed AbbVie 2017-11-29
NCT02582658 Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL) https://ClinicalTrials.gov/show/NCT02582658 Completed AbbVie 2017-01-12
NCT02581189 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada https://ClinicalTrials.gov/show/NCT02581189 Completed AbbVie 2017-12-20
NCT02557646 An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02557646 Completed Hoffmann-La Roche 2014-03-31
NCT02556307 A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients https://ClinicalTrials.gov/show/NCT02556307 Completed Hoffmann-La Roche 2014-07-31
NCT02545335 Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02545335 Active, not recruiting Medical University of Graz 2020-12-31
NCT02531269 Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period https://ClinicalTrials.gov/show/NCT02531269 Completed Bristol-Myers Squibb 2016-02-29
NCT02528461 Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02528461 Completed University of Aarhus 2019-01-31
NCT02526641 Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02526641 Active, not recruiting University of Aarhus 2019-03-31
NCT02508090 Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin https://ClinicalTrials.gov/show/NCT02508090 Completed Hoffmann-La Roche 2017-01-13
NCT02452814 Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection https://ClinicalTrials.gov/show/NCT02452814 Completed Hoffmann-La Roche 2017-05-03
NCT02439918 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa https://ClinicalTrials.gov/show/NCT02439918 Completed Université de Sherbrooke 2012-08-31
NCT02333292 Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions https://ClinicalTrials.gov/show/NCT02333292 Recruiting Valme University Hospital 2020-11-30
NCT02106156 Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists) https://ClinicalTrials.gov/show/NCT02106156 Completed Hoffmann-La Roche 2013-09-30
NCT02068963 Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing https://ClinicalTrials.gov/show/NCT02068963 Completed Hologic, Inc. 2015-04-30
NCT02065999 Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients https://ClinicalTrials.gov/show/NCT02065999 Recruiting Kirby Institute 2022-04-30
NCT01310205 Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV https://ClinicalTrials.gov/show/NCT01310205 Completed SciClone Pharmaceuticals 2012-03-31
NCT01272479 Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01272479 Completed Istanbul University 2010-03-31
NCT02057003 Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients https://ClinicalTrials.gov/show/NCT02057003 Recruiting Valme University Hospital 2020-12-31
NCT04202081 Voices From the Black Community: Hepatitis C Research Participation https://ClinicalTrials.gov/show/NCT04202081 Completed University of North Carolina, Chapel Hill 2020-05-15
NCT02951364 Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea https://ClinicalTrials.gov/show/NCT02951364 Recruiting Gilead Sciences 2021-10-31
NCT02011932 Prospective Observational Study of Disease Progression in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02011932 Active, not recruiting Beijing YouAn Hospital 2011-06-30
NCT02006823 Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02006823 Completed Duke University 2014-07-31
NCT01980290 Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01980290 Completed Janssen Pharmaceutica N.V., Belgium 2015-02-28
NCT01945008 Observational Study in HCV Chronic Infection https://ClinicalTrials.gov/show/NCT01945008 Completed Istituto Superiore di Sanità 2015-11-30
NCT01884402 Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4 https://ClinicalTrials.gov/show/NCT01884402 Completed Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 2014-05-31
NCT01850745 Multidisciplinary Support Program in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01850745 Completed Parc de Salut Mar 2009-01-31
NCT01771653 Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT01771653 Completed Southern Illinois University 2015-07-31
NCT01750216 An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT01750216 Completed Hoffmann-La Roche 2015-01-31
NCT01711164 The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis https://ClinicalTrials.gov/show/NCT01711164 Completed University Health Network, Toronto 2016-05-31
NCT01705717 A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01705717 Completed Hoffmann-La Roche 2012-05-01
NCT01679834 An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01679834 Completed Hoffmann-La Roche 2017-07-14
NCT01671046 An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT01671046 Completed Hoffmann-La Roche 2015-12-31
NCT01667081 Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) https://ClinicalTrials.gov/show/NCT01667081 Enrolling by invitation Merck Sharp & Dohme Corp. 2021-05-24
NCT01659567 A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C https://ClinicalTrials.gov/show/NCT01659567 Completed Hoffmann-La Roche 2015-10-20
NCT01641094 Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms https://ClinicalTrials.gov/show/NCT01641094 Completed Foundation for Liver Research 2014-06-30
NCT01634919 Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin https://ClinicalTrials.gov/show/NCT01634919 Completed Seoul National University Boramae Hospital 2017-02-17
NCT01609049 An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis https://ClinicalTrials.gov/show/NCT01609049 Completed Hoffmann-La Roche 2015-06-22
NCT01604291 An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01604291 Completed Hoffmann-La Roche 2016-02-10
NCT01544582 Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518) https://ClinicalTrials.gov/show/NCT01544582 Completed Merck Sharp & Dohme Corp. 2015-07-31
NCT01525810 Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial https://ClinicalTrials.gov/show/NCT01525810 Completed Bristol-Myers Squibb 2014-11-30
NCT01514890 French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin https://ClinicalTrials.gov/show/NCT01514890 Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2014-03-31
NCT01508130 An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT01508130 Completed Hoffmann-La Roche 2014-03-31
NCT01492504 Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial https://ClinicalTrials.gov/show/NCT01492504 Completed Bristol-Myers Squibb 2018-03-16
NCT01464008 The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01464008 Completed Beijing Ditan Hospital 2011-05-31
NCT01457768 A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response https://ClinicalTrials.gov/show/NCT01457768 Completed Gilead Sciences 2018-04-09
NCT01457755 Gilead Sustained Virologic Response (SVR) Registry https://ClinicalTrials.gov/show/NCT01457755 Completed Gilead Sciences 2017-03-28
NCT01453244 Pharmacogenomic Research in Korean Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT01453244 Completed Inje University 2013-03-31
NCT01447446 An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01447446 Completed Hoffmann-La Roche 2015-07-31
NCT01416610 An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy https://ClinicalTrials.gov/show/NCT01416610 Completed Hoffmann-La Roche 2014-10-31
NCT01403181 Effect of Boceprevir on HCV-specific T Cell Responses https://ClinicalTrials.gov/show/NCT01403181 Completed Azienda Ospedaliero-Universitaria di Parma 2013-10-31
NCT01402583 Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01402583 Completed University of Modena and Reggio Emilia 2011-08-31
NCT01392742 An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin https://ClinicalTrials.gov/show/NCT01392742 Completed Hoffmann-La Roche 2014-07-31
NCT03348059 Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy https://ClinicalTrials.gov/show/NCT03348059 Completed Hospices Civils de Lyon 2016-11-30
NCT01344889 An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C) https://ClinicalTrials.gov/show/NCT01344889 Completed Hoffmann-La Roche 2013-06-30
NCT01342003 HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b https://ClinicalTrials.gov/show/NCT01342003 Completed Azienda Ospedaliera San Camillo Forlanini 2010-07-31
NCT01335230 The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients https://ClinicalTrials.gov/show/NCT01335230 Completed University of Cincinnati 2013-01-31
NCT04352309 Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis https://ClinicalTrials.gov/show/NCT04352309 Recruiting AbbVie 2021-04-20
NCT04330508 Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial https://ClinicalTrials.gov/show/NCT04330508 Recruiting Postgraduate Institute of Medical Education and Research 2020-10-31
NCT04214028 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus https://ClinicalTrials.gov/show/NCT04214028 Recruiting AbbVie 2024-12-30
NCT04189627 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation https://ClinicalTrials.gov/show/NCT04189627 Recruiting AbbVie 2021-03-01
NCT04094272 Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT04094272 Completed Kantonsspital Olten 2019-05-01
NCT04071353 Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT04071353 Recruiting Beijing Ditan Hospital 2020-08-01
NCT03993925 Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong https://ClinicalTrials.gov/show/NCT03993925 Recruiting The University of Hong Kong 2020-09-30
NCT03880682 Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT03880682 Completed Istanbul University 2019-06-15
NCT03868163 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation https://ClinicalTrials.gov/show/NCT03868163 Active, not recruiting AbbVie 2020-08-15
NCT03346941 Side Effects After Direct-acting Antiviral Treatment https://ClinicalTrials.gov/show/NCT03346941 Completed Hospices Civils de Lyon 2017-09-30
NCT03740906 Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting https://ClinicalTrials.gov/show/NCT03740906 Recruiting Kirby Institute 2021-01-31
NCT03740230 An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs https://ClinicalTrials.gov/show/NCT03740230 Recruiting AbbVie 2022-09-30
NCT03693586 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis https://ClinicalTrials.gov/show/NCT03693586 Recruiting Hospital General de Mexico 2020-05-01
NCT03570112 Transmission of Chronic Hepatitis C in Pregnancy https://ClinicalTrials.gov/show/NCT03570112 Recruiting The Christ Hospital 2020-06-30
NCT03566563 Epidemiology of Chronic Hepatitis C and Disease Modelling https://ClinicalTrials.gov/show/NCT03566563 Recruiting Changi General Hospital 2019-02-18
NCT03551002 Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego https://ClinicalTrials.gov/show/NCT03551002 Recruiting University of California, San Diego 2020-12-31
NCT03520660 People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents https://ClinicalTrials.gov/show/NCT03520660 Recruiting National Institutes of Health Clinical Center (CC) 2032-12-31
NCT03513796 Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside https://ClinicalTrials.gov/show/NCT03513796 Active, not recruiting NHS Tayside 2018-12-31
NCT03510637 “Real Life” Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt https://ClinicalTrials.gov/show/NCT03510637 Recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2020-08-31
NCT03500562 Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) https://ClinicalTrials.gov/show/NCT03500562 Recruiting Bristol-Myers Squibb 2021-12-31
NCT03459768 Cohort Study on People Who Inject Drugs in Senegal https://ClinicalTrials.gov/show/NCT03459768 Active, not recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2020-02-29
NCT03423641 An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT03423641 Completed Kaiser Permanente 2017-12-31
NCT03413696 Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients https://ClinicalTrials.gov/show/NCT03413696 Enrolling by invitation University of California, San Diego 2019-12-31
NCT01206933 The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System https://ClinicalTrials.gov/show/NCT01206933 Completed George Washington University 2015-06-30
NCT01200225 An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) https://ClinicalTrials.gov/show/NCT01200225 Completed Hoffmann-La Roche 2013-06-30
NCT01159613 Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection? https://ClinicalTrials.gov/show/NCT01159613 Completed Ziv Hospital 2008-10-31
NCT01112033 Biliverdin Reductase A in Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT01112033 Completed Charles University, Czech Republic 2013-03-31
NCT01098097 Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) https://ClinicalTrials.gov/show/NCT01098097 Completed Merck Sharp & Dohme Corp. 2011-10-31
NCT01070550 PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a) https://ClinicalTrials.gov/show/NCT01070550 Completed Hoffmann-La Roche 2011-07-31
NCT01066819 PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b https://ClinicalTrials.gov/show/NCT01066819 Completed Hoffmann-La Roche 2011-08-31
NCT01066793 PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b https://ClinicalTrials.gov/show/NCT01066793 Completed Hoffmann-La Roche 2011-03-31
NCT01054742 Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2) https://ClinicalTrials.gov/show/NCT01054742 Completed Merck Sharp & Dohme Corp. 2011-06-30
NCT01033045 Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure https://ClinicalTrials.gov/show/NCT01033045 Completed Fundacion IMIM 2013-07-31
NCT00998621 ADHEPTA Study: Adherence Questionnaire in Hepatitis C https://ClinicalTrials.gov/show/NCT00998621 Completed Fundacion IMIM 2010-09-30
NCT00863109 Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) https://ClinicalTrials.gov/show/NCT00863109 Completed Merck Sharp & Dohme Corp. 2013-05-31
NCT03000023 Anticipated and Perceived Benefits Following Hepatitis C Treatment https://ClinicalTrials.gov/show/NCT03000023 Completed University of North Carolina, Chapel Hill 2018-07-31
NCT03042520 Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment https://ClinicalTrials.gov/show/NCT03042520 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2022-09-30
NCT03342261 Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia https://ClinicalTrials.gov/show/NCT03342261 Completed Hospices Civils de Lyon 2017-11-01
NCT03246048 Long Term Follow-up of Hepatitis C Cured Patients https://ClinicalTrials.gov/show/NCT03246048 Active, not recruiting Hospital Universitari Vall d’Hebron Research Institute 2021-01-31
NCT02907996 Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea https://ClinicalTrials.gov/show/NCT02907996 Recruiting Gilead Sciences 2021-09-30
NCT02581163 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium https://ClinicalTrials.gov/show/NCT02581163 Completed AbbVie 2018-02-12
NCT02578693 Follow up of IFN Vs DAAs HCV SVR (IFDACS Study) https://ClinicalTrials.gov/show/NCT02578693 Recruiting Humanity and Health Research Centre 2020-12-31
NCT02505243 Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens https://ClinicalTrials.gov/show/NCT02505243 Completed Radboud University 2016-06-30
NCT01280656 A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION) https://ClinicalTrials.gov/show/NCT01280656 Completed Hoffmann-La Roche 2012-11-30
NCT01577069 Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir https://ClinicalTrials.gov/show/NCT01577069 Completed Association HGE CHU Bordeaux Sud 2013-01-31
NCT00770198 sgp130 in Chronic Human Liver Disease https://ClinicalTrials.gov/show/NCT00770198 Completed Erasme University Hospital 2007-01-31
NCT00736242 Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) https://ClinicalTrials.gov/show/NCT00736242 Completed Merck Sharp & Dohme Corp. 2011-12-31
NCT00728494 Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) https://ClinicalTrials.gov/show/NCT00728494 Completed Merck Sharp & Dohme Corp. 2007-12-31
NCT00727311 Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) https://ClinicalTrials.gov/show/NCT00727311 Completed Merck Sharp & Dohme Corp. 2009-06-30
NCT00726557 Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) https://ClinicalTrials.gov/show/NCT00726557 Completed Merck Sharp & Dohme Corp. 2009-01-31
NCT00725751 Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) https://ClinicalTrials.gov/show/NCT00725751 Completed Merck Sharp & Dohme Corp. 2011-03-31
NCT00725205 Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) https://ClinicalTrials.gov/show/NCT00725205 Completed Merck Sharp & Dohme Corp. 2010-10-31
NCT00724893 Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) https://ClinicalTrials.gov/show/NCT00724893 Completed Merck Sharp & Dohme Corp. 2012-08-31
NCT00724854 Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) https://ClinicalTrials.gov/show/NCT00724854 Completed Merck Sharp & Dohme Corp. 2009-09-30
NCT00724464 Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) https://ClinicalTrials.gov/show/NCT00724464 Completed Merck Sharp & Dohme Corp. 2010-10-31
NCT00724451 Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) https://ClinicalTrials.gov/show/NCT00724451 Completed Merck Sharp & Dohme Corp. 2011-10-31
NCT00724373 Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) https://ClinicalTrials.gov/show/NCT00724373 Completed Merck Sharp & Dohme Corp. 2009-02-28
NCT00724295 Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) https://ClinicalTrials.gov/show/NCT00724295 Completed Merck Sharp & Dohme Corp. 2008-12-31
NCT00724230 Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) https://ClinicalTrials.gov/show/NCT00724230 Completed Merck Sharp & Dohme Corp. 2008-12-31
NCT00723931 PegIntron Injection Surveillance Plan (Study P04123) https://ClinicalTrials.gov/show/NCT00723931 Completed Merck Sharp & Dohme Corp. 2009-11-30
NCT00723892 Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252) https://ClinicalTrials.gov/show/NCT00723892 Completed Merck Sharp & Dohme Corp. 2009-05-31
NCT00723645 Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) https://ClinicalTrials.gov/show/NCT00723645 Completed Merck Sharp & Dohme Corp. 2010-04-30
NCT00723632 Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) https://ClinicalTrials.gov/show/NCT00723632 Completed Merck Sharp & Dohme Corp. 2010-12-31
NCT00709228 Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793) https://ClinicalTrials.gov/show/NCT00709228 Completed Merck Sharp & Dohme Corp. 2008-11-30
NCT00709059 Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) https://ClinicalTrials.gov/show/NCT00709059 Completed Merck Sharp & Dohme Corp. 2009-12-31
NCT00707603 Chronic Hepatitis C and Insulin Resistance https://ClinicalTrials.gov/show/NCT00707603 Completed Garvan Institute of Medical Research 2008-12-31
NCT00705666 Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) https://ClinicalTrials.gov/show/NCT00705666 Completed Merck Sharp & Dohme Corp. 2008-07-31
NCT00705263 Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED) https://ClinicalTrials.gov/show/NCT00705263 Completed Schering-Plough 2008-05-31
NCT00705224 Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) https://ClinicalTrials.gov/show/NCT00705224 Completed Merck Sharp & Dohme Corp. 2010-08-31
NCT00704964 Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) https://ClinicalTrials.gov/show/NCT00704964 Completed Merck Sharp & Dohme Corp. 2009-10-31
NCT00704717 Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) https://ClinicalTrials.gov/show/NCT00704717 Completed Merck Sharp & Dohme Corp. 2007-12-31
NCT00704522 Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) https://ClinicalTrials.gov/show/NCT00704522 Completed Merck Sharp & Dohme Corp. 2009-04-30
NCT00700401 POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). https://ClinicalTrials.gov/show/NCT00700401 Completed Hoffmann-La Roche 2010-11-30
NCT00659256 Hepatitis C Treatment and Atherosclerosis https://ClinicalTrials.gov/show/NCT00659256 Completed National Institutes of Health Clinical Center (CC) NA
NCT00610597 Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease https://ClinicalTrials.gov/show/NCT00610597 Completed Erasme University Hospital 2007-01-31
NCT00606528 FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy https://ClinicalTrials.gov/show/NCT00606528 Completed University Health Network, Toronto 2013-07-31
NCT00473993 Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland https://ClinicalTrials.gov/show/NCT00473993 Completed Seidenberg, Arztpraxis A., M.D. NA
NCT00466336 Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices https://ClinicalTrials.gov/show/NCT00466336 Completed National Taiwan University Hospital 2006-12-31
NCT00466271 Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study https://ClinicalTrials.gov/show/NCT00466271 Completed National Taiwan University Hospital 2008-11-30
NCT00422838 Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients. https://ClinicalTrials.gov/show/NCT00422838 Completed Foundation for Liver Research 2010-06-30
NCT00361179 Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00361179 Completed National Taiwan University Hospital NA
NCT00322179 Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00322179 Completed Palo Alto Veterans Institute for Research 2007-11-30
NCT00227149 Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00227149 Completed University of Wuerzburg NA
NCT00216775 Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00216775 Completed Kyoto University 2008-05-31
NCT00187473 Natural History of Hepatitis C in Patients With Normal Liver Tests https://ClinicalTrials.gov/show/NCT00187473 Active, not recruiting University of California, San Francisco 2020-12-31
NCT00727259 Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) https://ClinicalTrials.gov/show/NCT00727259 Completed Merck Sharp & Dohme Corp. 2008-04-30

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04460157 Prediction of Liver-related Outcomes After HCV Cure https://ClinicalTrials.gov/show/NCT04460157 Recruiting Hospital Universitario de Valme 2021-05-31
NCT02969668 Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients https://ClinicalTrials.gov/show/NCT02969668 Active, not recruiting Universitätsklinikum Hamburg-Eppendorf 2018-10-31
NCT02628717 Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC) https://ClinicalTrials.gov/show/NCT02628717 Completed Medical University of Vienna 2016-12-31
NCT02510300 A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials https://ClinicalTrials.gov/show/NCT02510300 Enrolling by invitation Gilead Sciences 2024-11-30
NCT02292706 A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT02292706 Active, not recruiting Gilead Sciences 2023-01-31
NCT02250001 Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02250001 Completed Bristol-Myers Squibb 2017-01-20
NCT01908660 Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions https://ClinicalTrials.gov/show/NCT01908660 Completed Valme University Hospital 2015-09-30
NCT04301882 An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT04301882 Recruiting Beijing Ditan Hospital 2020-09-01
NCT04211844 Metabolic Changes in Chronic HCV Patients Receiving DAAS https://ClinicalTrials.gov/show/NCT04211844 Recruiting Ain Shams University 2020-04-30
NCT03226509 Transforming the Cascade Of Hepatitis C Care https://ClinicalTrials.gov/show/NCT03226509 Active, not recruiting University of Pittsburgh 2019-09-30